GlassScriptPhysician profile
Tania M Lebaron
NPI 1316945017
$2,615.47
in general payments reported to CMS, 2019-2025
31 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $148 · 2021: $169 · 2022: $286 · 2023: $519 · 2024: $140 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.71 | 2022-2025 | |
| Pfizer INC. | $354.71 | 2019-2025 | |
| Glaxosmithkline, LLC. | $287.36 | 2019-2023 | Arexvy, Trelegy Ellipta, Nucala |
| Novo Nordisk INC | $273.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $165.27 | 2019-2021 | |
| Dexcom, INC. | $148.73 | 2022-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $124.50 | 2019-2022 | |
| Inspire Medical Systems, INC. | $117.76 | 2023-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.38 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $67.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $53.12 | 2019-2025 | Enflonsia, Gardasil 9, Vaxneuvance |
| Amgen INC. | $51.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.29 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $45.10 | 2019 | |
| Nestle Healthcare Nutrition INC. | $44.54 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.97 | 2019-2021 | |
| Lilly USA, LLC | $35.02 | 2019-2022 | |
| Axsome Therapeutics, INC. | $29.20 | 2025 | Symbravo |
| Medtronic, INC. | $27.97 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $27.07 | 2024 | |
| Ironshore Pharmaceuticals INC. | $25.31 | 2019-2020 | |
| Astellas Pharma US INC | $24.07 | 2019-2023 | Veozah |
| Actelion Pharmaceuticals US, INC. | $22.17 | 2025 | Opsynvi |
| Krystal Biotech INC | $21.46 | 2025 | Vyjuvek |
| Sunovion Pharmaceuticals INC. | $19.75 | 2019 | |
| Corcept Therapeutics | $17.00 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $16.76 | 2021 | |
| Horizon Therapeutics Plc | $16.44 | 2019 | |
| Allergan, INC. | $15.61 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.64 | 2025 | Zoryve |
| Vertiflex, INC. | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tania Lebaron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.